A
Status-Quo-PlayerAgilent Technologies
$117.50
+2.12%
as of 13 Apr
Power Core
Agilent's moat is the compounding switching cost of integrated analytical workflows, where hardware, consumables, software, and validated methods create a system-level lock-in that no single competitor can replicate across the full stack.
Direction of Movement
Lateral Trajectory With Cyclical Recovery Emerging Slowly
ROC 200
-3.0%
A
Agilent Technologies
$117.50
+2.12%
as of 13 Apr
DCF Fair Value: $78.11
Market data unavailable
Company Profile
Agilent Technologies Inc. provides application-focused solutions for life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three key segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment delivers instruments, software, and services to identify, quantify, and analyze physical and biological properties of substances, supporting clinical and life sciences research at molecular and cellular levels. The Diagnostics and Genomics segment supplies reagents, instruments, software, consumables, and active pharmaceutical ingredients for oligo-based therapeutics, advancing genomics, pathology, and companion diagnostics. Agilent CrossLab offers startup support, operational training, compliance services, software-as-a-service, asset management, and consultative services to optimize laboratory performance. Notable products include liquid chromatography systems, mass spectrometry, and innovations like the Altura line of HPLC columns for biotherapeutic testing, xCELLigence RTCA eSight with 21 CFR Part 11 compliance software, and Insight Series for airport security screening. Founded in 1999 and headquartered in Santa Clara, California, Agilent Technologies Inc. plays a vital role in enabling scientific breakthroughs across pharmaceuticals, biotechnology, and environmental testing.